References: Palivizumab (Synagis®)

1. AstraZeneca Canada Inc. (July 9, 2021). Product Monograph Synagis® (palivizumab) solution for injection 50 mg/0.5ml and 100 mg/ml Intramuscular Injections. 
   https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/synagis-product-monograph-en.pdf
2. Committee on Infectious Diseases American Academy of Pediatrics. Red Book: 2018-2021 Report of the Committee on Infectious Diseases. Itasca, IL; 2018. URL (528 https://online.statref.com/Document.aspx?FxId=76&SessionID=2A3953ELWGUKXWRS#H&1&ChaptersTab&UHOsAWxnX1ooAz3HP2xxIw!!&&76). Accessed October 02, 2018.
3. Canadian Communicable Disease Report, Statement of the recommended use of monoclonal anti-RSV antibody, 15 September 2003, Volume 29, ACS-7,8. 
4. Position statement: Preventing hospitalizations for respiratory syncytial virus infection. Robinson Joan L, Le Saux Nicole; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 2015; 20(6):321-26
5. Canadian Pediatric Society Position Statement. Use of palivizumab in children with congenital heart disease. Paediatrics & Child Health 2009; Vol 14 No 8. 
6. Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40. 
7. Ryan VR, Langley JM, Dodds L, Andreou P. Estimating Respiratory Syncytial Virus –associated hospitalization in the first year of life among infants born at 32 – 35 weeks gestation. Pediatr Infect Dis J 2016;35:851-855 doi: 10.1097/INF.0000000000001186